I don't want to beat the HIV issue to death, but leronilmab for COVID would be mostly a in-patient drug, whereas for HIV it would be outpatient. In terms of the inevitable forthcoming challenges in the medico-economic issues, marketing is remarkably different. The audience and barriers for in-patient would be ICU, ID, and IM prescribe rs, as well the pharmacy dept. and ultimately the c-suite. For HIV most ID providers don't want to take care of AIDS and relegate these patients to ID-HIV specialist a much smaller cohort to market to, and a very close community as well. The third leg of evidence based medicine is clinical experience on the individual provider level. The dissemination of information would be rapid.